Which IL-5 Inhibitors are available?

This directory covers 2: Fasenra, Nucala.

IL-5 Inhibitors (Severe Asthma) — Drugs in This Class, Uses & How They Compare

IL-5 Inhibitors (Severe Asthma)

Also called anti-IL-5 biologics, eosinophilic asthma biologics

IL-5 is the signal that tells eosinophils — a type of white blood cell — to grow and survive. In severe eosinophilic asthma those cells flood the airways and drive attacks. Blocking IL-5, or the receptor it binds to, strips the eosinophils out and can roughly halve the rate of asthma exacerbations in people whose disease is not controlled by inhalers alone.

Reviewed by the Priya Life Science Editorial Team, led by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from official FDA data · Last verified 7 Aug 2026 · Editorial standards

What this class is used for

Severe eosinophilic asthma, nasal polyps, eosinophilic granulomatosis with polyangiitis

2 IL-5 Inhibitors in this directory

Fasenra

Benralizumab

A biologic for severe eosinophilic asthma.

Nucala

Mepolizumab

An injectable biological therapy used to treat severe eosinophilic asthma.

Compare IL-5 Inhibitors side by side

Fasenra VS Nucala

Browse other drug classes

ARBs Anti-amyloid Antibodies Antibiotics Antibody-drug Conjugates Anticoagulants Anticonvulsants Antihistamines Antiplatelets Asthma & COPD Inhalers Atypical Antipsychotics BTK Inhibitors Beta Blockers CD20 Antibodies CDK4/6 Inhibitors CGRP Inhibitors COVID-19 Antivirals Checkpoint Inhibitors Cholinesterase Inhibitors Complement Inhibitors DPP-4 Inhibitors EGFR Inhibitors Enzyme Replacement Therapy GLP-1 Agonists Gene & Cell Therapies HIV Antiretrovirals Hepatitis C Antivirals IL-1 Inhibitors IL-17 Inhibitors IL-23 Inhibitors IL-6 Inhibitors Insulins JAK Inhibitors PARP Inhibitors PCSK9 Inhibitors Proton Pump Inhibitors SGLT2 Inhibitors SSRIs & SNRIs Statins TNF Inhibitors TTR Silencers Tyrosine Kinase Inhibitors

How this page is built

The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.

FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
Drugs@FDA ↗ First FDA approval date and the company holding the application
FDA Drug Shortage Database ↗ Current US supply / shortage status

Plain-English summaries and drug-class explainers are written and reviewed by the Priya Life Science editorial team, led by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 7 Aug 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.